Triazolam
Benzodiazepine — NERVOUS SYSTEM
Also known as: U 33,030, U-33,030, U33,030
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Triazolam is an ofp drug in the Benzodiazepine class catalogued in DrugCentral. It was first approved by the FDA in 1982. DrugCentral lists 16 molecular targets, including GABRG2|GABRB3|GABRA2, GABRG2|GABRA5|GABRB2 and GABRA1|GABRG2|GABRB2. Recorded indications include Insomnia.
- Approval status: ofp (first approved 1982 by the FDA).
- Drug class: Benzodiazepine.
- Molecular targets: GABRG2|GABRB3|GABRA2, GABRG2|GABRA5|GABRB2, GABRA1|GABRG2|GABRB2 and GABRD|GABRA1|GABRB1|GABRG2|GABRB3|GABRA5|GABRA3|GABRA2|GABRB2|GABRA4|GABRA6|GABRG1|GABRG3 (16 listed in DrugCentral).
- Indications: Insomnia.
- ATC code: N05CD05 (Benzodiazepine derivatives).
- Molecular formula: C17H12Cl2N4; molecular weight 343.21 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Insomnia
Contraindications (15)
- Alcohol intoxication
- Breastfeeding (mother)
- Chronic lung disease
- Depressive disorder
- Disease of liver
- Hypoalbuminemia
- Kidney disease
- Myasthenia gravis
- Pregnancy, function
- Psychotic disorder
- Sleep apnea
- Sleep automatism
- Substance abuse
- Suicidal thoughts
- Syncope
Mechanism & targets
| Established pharmacologic class | Benzodiazepine |
|---|
Molecular targets (16)
| Target | Gene | Action | Activity |
|---|---|---|---|
| GABA-A receptor alpha-2/beta-3/gamma-2 | GABRG2|GABRB3|GABRA2 | positive allosteric modulator | Ki 9.23 |
| GABA A receptor alpha-5/beta-2/gamma-2 | GABRG2|GABRA5|GABRB2 | positive allosteric modulator | Ki 9.22 |
| GABA-A receptor alpha-1/beta-2/gamma-2 | GABRA1|GABRG2|GABRB2 | positive allosteric modulator | Ki 9.15 |
| GABA-A receptor | GABRD|GABRA1|GABRB1|GABRG2|GABRB3|GABRA5|GABRA3|GABRA2|GABRB2|GABRA4|GABRA6|GABRG1|GABRG3 | positive allosteric modulator | Ki 9.10 |
| GABA-A receptor; anion channel | Gabrp|Gabrb1|Gabrd|Gabrg2|Gabra5|Gabra3|Gabrg1|Gabra2|Gabra4|Gabrg3|Gabra6|Gabra1|Gabrb3|Gabrb2|Gabrq|Gabre | unknown | Ki 9.10 |
| GABA-A receptor alpha-1/beta-3/gamma-2 | GABRA1|GABRG2|GABRB3 | positive allosteric modulator | Ki 9.10 |
| GABA-A receptor alpha-5/beta-3/gamma-2 | GABRG2|GABRB3|GABRA5 | positive allosteric modulator | Ki 9.02 |
| GABA A receptor alpha-3/beta-2/gamma-2 | GABRG2|GABRA3|GABRB2 | positive allosteric modulator | Ki 8.88 |
| GABA-A receptor alpha-3/beta-3/gamma-2 | GABRG2|GABRB3|GABRA3 | positive allosteric modulator | Ki 8.85 |
| GABA A receptor alpha-5/beta-2/gamma-3 | GABRA5|GABRB2|GABRG3 | positive allosteric modulator | Ki 8.70 |
| GABA A receptor alpha-5/beta-3/gamma-3 | GABRB3|GABRA5|GABRG3 | positive allosteric modulator | Ki 8.70 |
| GABA-A receptor alpha-1/beta-2/gamma-3 | GABRA1|GABRB2|GABRG3 | positive allosteric modulator | Ki 8.64 |
| GABA A receptor alpha-3/beta-2/gamma-3 | GABRA3|GABRB2|GABRG3 | positive allosteric modulator | Ki 8.11 |
| Platelet-activating factor receptor | PTAFR | unknown | Ki 5.88 |
| Cholecystokinin receptor type A | Cckar | unknown | IC50 4.41 |
| Cytochrome P450 3A4 | CYP3A4 | unknown | Ki 4.27 |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 1982-11-15 | FDA | — | PHARMACIA AND UPJOHN |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
N05CD05 | NERVOUS SYSTEM › PSYCHOLEPTICS › HYPNOTICS AND SEDATIVES › Benzodiazepine derivatives |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Sopor | 1337.5 |
| Drug abuse | 939.1 |
| Intentional self-injury | 316.3 |
| Intentional overdose | 257.0 |
| Overdose | 226.0 |
| Suicide attempt | 197.2 |
| Completed suicide | 155.6 |
| Toxicity to various agents | 141.8 |
| Alcohol interaction | 140.2 |
| Loss of consciousness | 133.0 |
| Bradyphrenia | 105.0 |
| Drug dependence | 91.8 |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Triazolam is on its molecule page.
| Molecular formula | C17H12Cl2N4 |
|---|---|
| Molecular weight | 343.21 g/mol |
| CAS number | 28911-01-5 |
| InChIKey | JOFWLTCLBGQGBO-UHFFFAOYSA-N |
| PubChem CID | 5556 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Triazolam used for?
DrugCentral lists the following indications for Triazolam: Insomnia.
How does Triazolam work?
Its molecular targets in DrugCentral include GABRG2|GABRB3|GABRA2 (positive allosteric modulator), GABRG2|GABRA5|GABRB2 (positive allosteric modulator), GABRA1|GABRG2|GABRB2 (positive allosteric modulator) and GABRD|GABRA1|GABRB1|GABRG2|GABRB3|GABRA5|GABRA3|GABRA2|GABRB2|GABRA4|GABRA6|GABRG1|GABRG3 (positive allosteric modulator).
When was Triazolam first approved?
Triazolam was first approved by the FDA in 1982.
What drug class does Triazolam belong to?
Triazolam is in the Benzodiazepine class.
What is the chemical formula of Triazolam?
Triazolam has the molecular formula C17H12Cl2N4 and a molecular weight of 343.21 g/mol.
Browse: all drugs starting with T · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 2729 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL646 — compound record and bioactivity
- PubChem CID 5556 — chemical identifiers
- DrugBank DB00897 — drug record
- FDA UNII 1HM943223R — substance identity
- DailyMed: FDA labels for Triazolam — current prescribing information (label search)
- UniProt P25105 (PTAFR) — target protein
- UniProt P08684 (CYP3A4) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.